Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2017
At a glance
- Drugs CLR 1404 I-131 (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Proof of concept
- Sponsors Cellectar Biosciences
- 08 Aug 2017 Data published in a Cellectar Biosciences Media Release.
- 08 Aug 2017 According to a Cellectar Biosciences media release, company continues to collect overall survival data on all evaluable trial participants and will provide timely updates, as appropriate.
- 08 Aug 2017 According to a Cellectar Biosciences media release, fourth cohort of this trial is fully enrolled, initial results from this cohort is expected by the close of the third quarter 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History